MX359398B - Compuestos para transduccion viral mejorada. - Google Patents

Compuestos para transduccion viral mejorada.

Info

Publication number
MX359398B
MX359398B MX2014003923A MX2014003923A MX359398B MX 359398 B MX359398 B MX 359398B MX 2014003923 A MX2014003923 A MX 2014003923A MX 2014003923 A MX2014003923 A MX 2014003923A MX 359398 B MX359398 B MX 359398B
Authority
MX
Mexico
Prior art keywords
viral transduction
methods
compounds
cells
compositions
Prior art date
Application number
MX2014003923A
Other languages
English (en)
Other versions
MX2014003923A (es
Inventor
Collins Heffner Garrett
Isaac Bassan Abraham
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47996444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359398(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of MX2014003923A publication Critical patent/MX2014003923A/es
Publication of MX359398B publication Critical patent/MX359398B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para mejorar la eficacia de transducción viral de células. Más particularmente, la presente invención proporciona métodos y materiales útiles para mejorar de manera segura y confiable la eficiencia de métodos para transducir células, tales como células madre hematopoyéticos (HSC) humanos, con virus y/o vectores virales. Las composiciones y métodos son útiles para indicaciones terapéuticas susceptibles de tratamiento con genoterapias de células madre hematopoyéticos.
MX2014003923A 2011-09-30 2012-09-28 Compuestos para transduccion viral mejorada. MX359398B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541736P 2011-09-30 2011-09-30
PCT/US2012/057987 WO2013049615A1 (en) 2011-09-30 2012-09-28 Compounds for improved viral transduction

Publications (2)

Publication Number Publication Date
MX2014003923A MX2014003923A (es) 2014-05-07
MX359398B true MX359398B (es) 2018-09-27

Family

ID=47996444

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003923A MX359398B (es) 2011-09-30 2012-09-28 Compuestos para transduccion viral mejorada.
MX2018011791A MX2018011791A (es) 2011-09-30 2014-03-31 Compuestos para transduccion viral mejorada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018011791A MX2018011791A (es) 2011-09-30 2014-03-31 Compuestos para transduccion viral mejorada.

Country Status (19)

Country Link
US (5) US9988644B2 (es)
EP (4) EP2760994B2 (es)
JP (2) JP6285863B2 (es)
KR (1) KR102011532B1 (es)
CN (2) CN108220246B (es)
AU (1) AU2012315699B2 (es)
BR (1) BR112014007782B1 (es)
CA (1) CA2850484C (es)
CY (1) CY1122654T1 (es)
DK (2) DK3269802T3 (es)
EA (1) EA032699B1 (es)
ES (3) ES2769270T3 (es)
IL (2) IL231812B (es)
IN (1) IN2014CN02518A (es)
MX (2) MX359398B (es)
PT (2) PT3269802T (es)
SG (2) SG11201401077PA (es)
UA (1) UA114796C2 (es)
WO (1) WO2013049615A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054271A1 (en) 2008-11-06 2010-05-14 Indiana University Research & Technology Corporation Materials and methds to enhance hematopoietic stem cells engraftment procedures
AU2012315699B2 (en) 2011-09-30 2017-08-17 Bluebird Bio, Inc. Compounds for improved viral transduction
CA2880808C (en) 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
EP2925864B1 (en) 2012-11-27 2018-10-31 The Children's Medical Center Corporation Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
WO2014110094A1 (en) 2013-01-09 2014-07-17 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
AU2014338555B2 (en) * 2013-10-24 2019-10-10 Fondazione Telethon Method
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
RU2707540C2 (ru) 2014-04-25 2019-11-27 Чилдрен'С Медикал Сентр Корпорэйшн Композиции и способы для лечения гемоглобинопатий
US11572543B2 (en) 2015-05-08 2023-02-07 The Children's Medical Center. Corporation Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
RU2630654C2 (ru) * 2015-07-29 2017-09-11 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов
CN105062979A (zh) * 2015-08-21 2015-11-18 昆明理工大学 一种培养戊型肝炎病毒的方法
WO2017139561A1 (en) * 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
ES2992295T3 (es) 2016-02-12 2024-12-11 Bluebird Bio Inc Composiciones potenciadoras de Vcn y métodos de uso de las mismas
EP3440191A4 (en) * 2016-04-07 2019-12-11 Bluebird Bio, Inc. CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
CA3041514A1 (en) 2016-10-24 2018-05-03 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
CN110582305A (zh) * 2017-03-29 2019-12-17 蓝鸟生物公司 用于治疗血红蛋白病的载体和组合物
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
WO2019055814A2 (en) * 2017-09-15 2019-03-21 The Medical College Of Wisconsin, Inc. EPOXYEICOSATRIENOIC ACID (EET) ANALOGUES TARGETING KIDNEYS
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
WO2019196816A1 (zh) * 2018-04-13 2019-10-17 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
CN109207427B (zh) * 2018-09-17 2020-12-08 诺未科技（银川）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
WO2019210301A1 (en) 2018-04-27 2019-10-31 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
WO2019213013A1 (en) 2018-05-02 2019-11-07 The Children's Medical Center Corporation Improved bcl11a micrornas for treating hemoglobinopathies
US12241079B2 (en) 2018-09-14 2025-03-04 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
US20210386787A1 (en) * 2018-10-12 2021-12-16 Life Technologies Corporation Hematopoietic Stem and Progenitor Cell Expansion System
EP3888693A4 (en) * 2018-11-30 2022-09-21 Kyoto University DRUG DELIVERY SYSTEM USING SOLUTION
WO2020264488A1 (en) * 2019-06-28 2020-12-30 The Children's Hospital Of Philadelphia Compositions and methods for treating anemia
CN114761567A (zh) * 2019-10-16 2022-07-15 奥查德疗法(欧洲)有限公司 用于修饰真核细胞的组合物和方法
CA3180217A1 (en) * 2020-06-02 2021-12-09 Gregory T. Bleck Nucleic acid constructs for protein manufacture
CN115125270A (zh) * 2021-03-22 2022-09-30 华东师范大学 一种α-珠蛋白过表达载体及其应用
CN113106098B (zh) * 2021-04-21 2022-04-01 贵州医科大学 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN113336833A (zh) * 2021-06-04 2021-09-03 广州伯尼兹生物科技有限公司 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
EP4569092A2 (en) 2022-08-11 2025-06-18 Fondazione Telethon ETS Gene therapy of lysosomal storage disorders
EP4602153A1 (en) 2022-10-11 2025-08-20 Fondazione Telethon ETS 3d cell culture methods
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
IT202300011790A1 (it) 2023-06-08 2024-12-08 Fond Telethon Ets Protocolli di manipolazione genica in cellule immunitarie
WO2025056970A1 (en) * 2023-09-12 2025-03-20 Virocell Biologics Ltd Mammalian cell culture additives
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
EP4640830A1 (en) 2024-04-23 2025-10-29 Fondazione Telethon ETS Means and methods for safe and efficient gene editing in cells

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568159A (en) 1896-06-26 1896-09-22 Veneering-machine
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
WO1995000657A1 (en) 1993-06-21 1995-01-05 The Uab Research Foundation Anti-sickling hemoglobin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5869039A (en) 1993-10-15 1999-02-09 Institut National De La Sante Et De La Recherche Medicale X-linked adrenoleukodystrophy gene and corresponding protein
WO1996009385A1 (en) 1994-09-19 1996-03-28 Massachusetts Institute Of Technology Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1997011604A1 (en) * 1995-09-29 1997-04-03 Indiana University Foundation Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP0951544A2 (en) 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
JP2002527101A (ja) 1998-10-16 2002-08-27 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US6822112B1 (en) 1999-08-13 2004-11-23 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivatives
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
DE60037905T2 (de) 1999-12-17 2009-01-29 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazin-basierte hemmer der glycogen-synthase-kinase 3
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
EP1385946B1 (en) 2001-05-01 2009-12-23 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003047635A1 (en) 2001-12-06 2003-06-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
EP1468094A4 (en) 2001-12-24 2005-01-26 Es Cell Int Pte Ltd METHOD OF TRANSDUCTING ES CELLS
JP2005516604A (ja) 2002-02-04 2005-06-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １３１、１４８、１９９、１２３０３、１３９０６、１５５１３、１７８２２、３０２、５６７７、１９４、１４３９３、２８０５９、７３６６、１２２１２、１９８１、２６１、１２４１６、２７０、１４１０、１３７、１８７１、１３０５１、１８４７、１８４９、１５４０２、３４０、１０２１７、８３７、１７６１、８９９０または１３２４９分子を用いて血液障害を処置するための方法および組成物
US7470709B2 (en) 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1581056B1 (en) 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutic retroviral vectors for gene therapy
AU2004227205B2 (en) 2003-04-08 2010-06-10 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
ATE488252T1 (de) 2003-05-05 2010-12-15 Virxsys Corp Erhöhte transduktion mit abc- transportersubstratenhemmern
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
WO2006047476A2 (en) 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
US8076315B2 (en) 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
RU2493252C2 (ru) 2006-03-24 2013-09-20 Чилдрен'З Медикал Сентер Корпорейшн Способ стимулирования экспансии гематопоэтических стволовых клеток
WO2007124578A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
RU2480213C2 (ru) 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Способ стимуляции регенерации тканей
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
EP3449923A1 (en) 2007-03-07 2019-03-06 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
WO2010054271A1 (en) 2008-11-06 2010-05-14 Indiana University Research & Technology Corporation Materials and methds to enhance hematopoietic stem cells engraftment procedures
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US11459545B2 (en) * 2009-11-15 2022-10-04 Indiana University Research And Technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors
AU2012315699B2 (en) 2011-09-30 2017-08-17 Bluebird Bio, Inc. Compounds for improved viral transduction
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
AU2014338555B2 (en) * 2013-10-24 2019-10-10 Fondazione Telethon Method
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
EP3313420B1 (en) * 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
KR20180033537A (ko) * 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
WO2017139561A1 (en) * 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
ES2992295T3 (es) * 2016-02-12 2024-12-11 Bluebird Bio Inc Composiciones potenciadoras de Vcn y métodos de uso de las mismas
GB201706394D0 (en) * 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques

Also Published As

Publication number Publication date
PT2760994T (pt) 2017-08-24
US11834668B2 (en) 2023-12-05
AU2012315699A1 (en) 2014-05-22
IN2014CN02518A (es) 2015-07-31
KR20140069315A (ko) 2014-06-09
MX2018011791A (es) 2021-12-08
KR102011532B1 (ko) 2019-08-16
PT3269802T (pt) 2020-01-28
US10907177B2 (en) 2021-02-02
UA114796C2 (uk) 2017-08-10
CN108220246B (zh) 2022-07-12
JP2014530012A (ja) 2014-11-17
JP2018099124A (ja) 2018-06-28
EP3269802B1 (en) 2019-10-23
JP6285863B2 (ja) 2018-02-28
AU2012315699B2 (en) 2017-08-17
IL231812A0 (en) 2014-05-28
US20240229070A1 (en) 2024-07-11
CA2850484A1 (en) 2013-04-04
NZ623341A (en) 2016-04-29
CN108220246A (zh) 2018-06-29
CA2850484C (en) 2021-01-26
EA201490627A1 (ru) 2014-11-28
US20200048657A1 (en) 2020-02-13
DK2760994T4 (da) 2021-10-11
IL231812B (en) 2021-03-25
ES2913633T3 (es) 2022-06-03
EP2760994B2 (en) 2021-09-15
SG11201401077PA (en) 2014-04-28
ES2632444T5 (es) 2022-03-02
WO2013049615A1 (en) 2013-04-04
US9988644B2 (en) 2018-06-05
EP2760994A1 (en) 2014-08-06
EA032699B1 (ru) 2019-07-31
SG10201602423TA (en) 2016-05-30
EP2760994B1 (en) 2017-05-31
IL281045A (en) 2021-04-29
US20210171980A1 (en) 2021-06-10
DK3269802T3 (da) 2020-02-03
IL281045B (en) 2022-02-01
BR112014007782A2 (pt) 2017-04-11
EP2760994B8 (en) 2017-07-26
US20140234278A1 (en) 2014-08-21
US10501759B2 (en) 2019-12-10
EP3269802A1 (en) 2018-01-17
JP6745826B2 (ja) 2020-08-26
EP4095236A1 (en) 2022-11-30
ES2769270T3 (es) 2020-06-25
US20180363004A1 (en) 2018-12-20
EP3656848A1 (en) 2020-05-27
BR112014007782B1 (pt) 2021-06-01
ES2632444T3 (es) 2017-09-13
EP3656848B1 (en) 2022-03-16
MX2014003923A (es) 2014-05-07
CN103958667A (zh) 2014-07-30
EP2760994A4 (en) 2015-03-11
DK2760994T3 (en) 2017-08-07
CY1122654T1 (el) 2021-03-12

Similar Documents

Publication Publication Date Title
MX2018011791A (es) Compuestos para transduccion viral mejorada.
WO2014026110A3 (en) Compounds for improved viral transduction
MX2013014544A (es) Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia.
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
GB201020995D0 (en) Biological materials and uses thereof
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
EA201391114A1 (ru) Способы использования alk-ингибиторов
MX2014003889A (es) Compuestos antivirales.
EA201171335A1 (ru) Вектор гена
MX388146B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
EA201370018A1 (ru) Составы рифаксимина и их применение
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2013004061A (es) Analogos de ciclosporina.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA201290813A1 (ru) Полиэпитопные конструкции и способы их получения и применения
MX351818B (es) Compuestos antivirales.
MX2013004062A (es) Analogos de ciclosporina.
WO2012094193A3 (en) Methods for enhancing the delivery of gene-transduced cells
WO2012175745A9 (en) Cell secreted proteins for the treatment of myocardial infarction
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
MX351991B (es) Adicion de hierro para mejorar cultivo celular.

Legal Events

Date Code Title Description
FG Grant or registration